Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.

Type II diabetes mellitus uncontrolled by any dual drug therapy.

One tablet once daily.

Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.

Known hypersensitivity to any of the components.

Trigem 1 is available as a strip of 10 tablets.

Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.

Type II diabetes mellitus uncontrolled by any dual drug therapy.

One tablet once daily.

Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.

Known hypersensitivity to any of the components.

Trigem 2 is available as a strip of 10 tablets.

It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.

• Non-insulin-dependent diabetes mellitus.
• In insulin dependent diabetes mellitus.
• Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.

Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.

Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.

Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.

Vogli is available as a strip of 10 tablets.

It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.

• Non-insulin-dependent diabetes mellitus.
• In insulin dependent diabetes mellitus.
• Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.

Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.

Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.

Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.

Vogli is available as a strip of 10 tablets.

Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.

Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients

One tablet twice daily.

Vogli is available as a strip of 10 tablets.

Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.

Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients

One tablet twice daily.

Vogli is available as a strip of 10 tablets.

Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.

• Post Prandial Hyperglycemia
• Type 2 diabetes not controlled with diet/ monotherapy
• Obese Type-2-Diabetic Patients
• Impaired Glucose Tolerance (IGT)
• Adjuvant to Insulin therapy in Type-1 Diabetic.

1 tablet with each major meal

Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.

Pregnancy, Liver disease, Kidney failure.

Vogli is available as a strip of 10 tablets.

Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.

• Post Prandial Hyperglycemia
• Type 2 diabetes not controlled with diet/ monotherapy
• Obese Type-2-Diabetic Patients
• Impaired Glucose Tolerance (IGT)
• Adjuvant to Insulin therapy in Type-1 Diabetic.

1 tablet with each major meal

Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.

Pregnancy, Liver disease, Kidney failure.

Vogli is available as a strip of 10 tablets.

Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.

Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients

One tablet twice daily.

Vogli is available as a strip of 10 tablets.

Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.

Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients

One tablet twice daily.

Vogli is available as a strip of 10 tablets.

• Type II Diabetes

Glytrin is available as a strip of 10 tablets.

• Type II Diabetes

Glytrin Met is available as a strip of 10 tablets.